x
ServiziMenu principaleHome
You are here: Home > Educational Opportunities > Past events > 2021 > Certificate of Competence in Lymphoma - fifth cohort (CCL5)
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Certificate of Competence in Lymphoma - fifth cohort (CCL5)

04.02.2021  -  19.05.2022

APPLICATION CLOSED

POSTGRADUATE PROGRAMME

Lymphoma

Description

Certificate of Competence in Lymphoma (CCL) programme
Programme Chairs: James Armitage, US; Franco Cavalli, CH; Manuela Hoechstetter, DE; Stephan Stilgenbauer, DE

The European School of Oncology (ESO) in cooperation with Ulm University has developed a post-graduate curriculum of studies designed for oncologists, haematologists and graduates in natural sciences with experience in oncology,

The objective of the programme is to advance the knowledge and science in the management of lymphoma patients with a curriculum that extends over a period of 15 months and includes three seminars and four e-learning modules.

The programme is academically recognised with 14 European Credit Transfer and Accumulation System Points (ECTS) by Ulm University and upon successful completion, participants obtain an academic certificate and a diploma supplement issued by Ulm University.

The current CCL cohort started in February 2021 and will conclude in May 2022. The subsequent cohort will run from 2023 to 2024. Admission to the programme is by competitive application only and is limited to 25 participants.

Programme

Block 1 - 04.02.2021 / 07.02.2021 - Bellinzona, Switzerland (Virtual)

CCL5: Seminar 1 + LyFE

Block 2 - 04.02.2021 / 05.04.2021 - Online

CCL5: Module 1: Basic research, epidemiology and pathology of lymphoma

Block 3 - 01.04.2021 / 31.07.2021 - Online

CCL5: Module 2: Principles of diagnostics, management and clinical trials

Block 4 - 18.06.2021 / 22.06.2021 - Lugano, Switzerland (Virtual)

CCL5: Seminar 2 + ICML

Block 5 - 01.08.2021 / 30.11.2021 - Online

CCL5: Module 3: Lymphoma subtypes Part 1 - Mature B-cell neoplasms

Block 6 - 01.12.2021 / 30.04.2022 - Online

CCL5: Module 4: Lymphoma subtypes Part 2 - PTLD, T-cell and NK-cell neoplasms and Hodgkin lymphoma

Block 7 - 15.05.2022 / 19.05.2022 - Ulm, Germany

CCL5: Seminar 3

Faculty

Silvia Alberti-Violetti, Domodossola, IT
James O. Armitage, University of Nebraska Medical Center, Dept. of Oncology and Hematology, Omaha, US
Andishe Attarbaschi, Saint Anna Children's Hospital, Dept. of Paediatrics, Vienna, AT
Sally Barrington, St Thomas' Hospital, Nuclear Medicine PET Imaging Centre, London, UK
Francesco Bertoni, IOR Institute of Oncology Research, Lymphoma & Genomics Research Program, Bellinzona, CH
Peter Borchmann, University Hospital Cologne, Dept. of Internal Medicine I, Haemato-Oncology Unit, Cologne, DE
Penelope Bradbury, Princess Margaret Cancer Centre, Divistion of Medical Oncology and Hematology, Toronto, ON, CA
Paul Bröckelmann, University Hospital of Cologne, Dept. of Internal Medicine, Köln, DE
George Calin, The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Division of Cancer Medicine, Houston, TX, US
Elias Campo, Hospital Clinic of the University of Barcelona, Anatomic Pathology Dept., Barcelona, ES
Luciano Cascione, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Carla Casulo, University of Rochester Medical Center, Dept. of Medicine, Hematology/Oncology, Rochester, US
Franco Cavalli, Oncology Institute of Southern Switzerland, Ufficio Prof. Cavalli, Bellinzona, CH
Bruce D. Cheson, The Lymphoma Research Foundation, Research Dept., New York, US
Joseph M. Connors, University of British Columbia Cancer Agency, Lymphoma Tumor Group, Vancouver, CA
Andrew Davies, General Hospital, Cancer Sciences Division, Somers Cancer Research Building, Southampton, UK
Daphne De Jong, Amsterdam University Medical Centre, Hemato-Pathology Dept., Amsterdam, NL
Laurence de Leval, Lausanne University Hospital, Pathology Department, Lausanne, CH
Jan Delabie, University of Toronto, Hematopathology and Transfusion Medicine, Toronto, ON, CA
Martin Dreyling, Munich University Hospital, Medical Clinic III, Munich, DE
Kieron Dunleavy, Georgetown University, Lombardi Cancer Center, Washington, DC, US
Dennis Eichenauer, University Clinic Cologne, First Department of Internal Medicine,, Cologne, DE
Dima El-Sharkawi, The Royal Marsden Hospital, Dept. of Haematology, London, UK
Andreas Engert, University Clinic Cologne, Clinic I for Internal Medicine, Cologne, DE
Pedro Farinha, BC Cancer Agency, BCCA Centre for Lymphoid Cancer, Vancouver, CA
Massimo Federico, University of Modena and Reggio Emilia (UNIMORE), Policlinico, Modena, IT
Andrés J. M. Ferreri, IRCCS San Raffaele Scientific Institute, Lymphoma Unit, Milan, IT
Jamie Flerlage, St. Jude Children's Research Hospital, Dept. of Oncology, Memphis, TN, US
Francesco Forconi, University Hospital Southampton, Lymphoma clinic, Southampton, UK
Francine Foss, Yale University School of Medicine, Section of Hematology and Bone Marrow Transplantation, New Haven, CT, US
Gianluca Gaidano, Torino, IT
Roger Geiger, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Paolo Ghia, Università Vita Salute San Raffaele, Division of Experimental Oncology, Milan, IT
Christian Gisselbrecht, St. Louis Hospital, Dept. of Haematology, Paris, FR
Bertram Glaß, Asklepios Klinik St. Georg, Haematology, Oncology and Stemcell Transplant Department, Hamburg, DE
Mary Gospodarowicz, Princess Margaret Cancer Centre - University of Toronto, Dept. of Radiation Oncology, Toronto, CA
Anton Hagenbeek, Academic Medical Centre, Dept. of Haematology, Amsterdam, NL
Gerhard Held, Saarland University, Hemato Oncology Dept., Kaiserslautern, DE
Manuela Hoechstetter, Klinikum Schwabing, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmed, Munich, DE
Georg Hopfinger, University Hospital Vienna, Dept. of Onco-Hematology, Vienna, AT
Werner Kempf, Kempf and Pfaltz Practice, Histological Diagnosis Dept., Zurich, CH
Won Seog Kim, Samsung Medical Centre, Hemato Oncology Dept., Seoul, KR
Eva Kimby, Karolinska Institute, Dept. of Hematology, Stockholm, SE
Stefan Knop, University Clinic Würzburg, Haematology Department, Würzburg, DE
Ralf Küppers, University of Duisburg-Essen, Medical School, Institute of Cell Biology (Cancer Research), Essen, DE
Georg Lenz, University Hospital Münster, Translational Oncology Dept., Münster, DE
T. Andrew Lister, St. Bartholomew's Hospital, Dept. of Medical Oncology, London, UK
Stefano Luminari, University of Modena and Reggio Emilia, Oncology Centre of Modena, Modena, IT
Ian Magrath, INCTR Int. Network for Cancer Treatment and Research, President Office, Brussels, BE
Liv Meert, EORTC, Data Management Dept., Brussels, BE
Daniel Mertens, University Hospital of Ulm and German Cancer Research Center DKFZ, Mechanisms of Leukemogenesis Lab, Ulm, DE
Alden Moccia, Oncology Institute of Southern Switzerland, Dept. of Medical Oncology, Locarno, CH
Peter Möller, Ulm University Medical Center, Institute of Pathology, Ulm, DE
Silvia Montoto, St Bartholomew's Hospital, Dept. of Haemato-Oncology, London, UK
Ryan Morin, British Columbia Cancer Agency, Department of Molecular Biology and Biochemistry, Vancouver, CA
Jessica Okosun, Buckhurst Hill, UK
Laura Pasqualucci, Herbert Irving Comprehensive Cancer Center, Institute for Cancer Genetics and Department of Pathology and Cell Biology, New York, US
Jakob R. Passweg, University Hospital Basel, Department of Haematology, Basel, CH
Lorenzo Patocchi, Cryms, DEV, Lamone, CH
Stefano Pileri, European Institute of Oncology, Haematopathology Division, Milan, IT
Alexandros Rampotas, Oxford University Hospitals, Dept. of Haematology, Oxford, UK
Andrea Rinaldi, Institute of Oncology Research (IOR), Lymphoma and Genomics Program, Bellinzona, CH
Danielle Rodin, Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, CA
Davide Rossi, Oncology Institue of Southern Switzerland (IOSI), Division of Haematology, Bellinzona, CH
Dietrich Rothenbacher, Ulm University, Institute of Epidemiology and Med. Biometry, Ulm, DE
Clementine Sarkozy, Institut Gustave Roussy, DITEP, Villejuif, FR
Kerry Savage, University of British Columbia, Faculty of Medicine, Vancouver, CA
Florian Scherer, Uniklinik Freiburg, ., Freiburg, DE
Uta Schmidt-Strassburger, Ulm University, Learning and Teaching, Medical Faculty, Ulm, DE
Stefan Schoenland, Heidelberg University Hospital, Dept. of Internal Medicine V, Heidelberg, DE
Laurie H. Sehn, British Columbia Cancer Agency, Centre for Lymphoid Cancer, Vancouver, CA
Diego Serraino, National Cancer Institute, IRCCS, Centro di Riferimento Oncologico, Aviano, IT
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Michele Spina, National Cancer Institute -Aviano, Division of Medical Oncology and Immune-related Tumors, Aviano, IT
Filippo Spriano, Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Bellinzona, CH
Anastasios Stathis, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
Stephan Stilgenbauer, University of Ulm, Dept. of Internal Medicine 3, Haematology and Oncology, Ulm, DE
Ralf Ulrich Trappe, DIAKO Hospital Bremen, Dept. of Internal Medicine II: Haematology and Oncology, Bremen, DE
Mariagrazia Uguccioni, IRB, ., Bellinzona, CH
Bastian von Tresckow, University of Essen, Haematology and Oncology Dept., Essen, DE
Julie M. Vose, University of Nebraska Medical Center, Division of Hematology/Oncology, Omaha, Nebraska, US
Emanuele Zucca, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology, Bellinzona, CH